Stay updated with breaking news from Service Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stock is trading at $28 compared with Eli Lilly’s $739 price tag. That could change if a trial of a pill version of its GLP-1 drug proves effective.
By Ben Glickman Shares of Synlogic fell sharply after the company opted to cease operations after stopping a clinical trial. The stock was down 55% to $1.56...
Health-care companies rose amid promising drug developments. Foghorn Therapeutics shares jumped by 56% after the biotech company said Eli Lilly will conduct...
New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.
Gilead shares have slid 11.3% since the biotech reported disappointing lung cancer drug trial data on Jan. 22.